Option Care Health Inc (OPCH)

Investment Committee Summary

Investment Thesis

Option Care Health delivers infusion therapy in patients' homes and at alternative sites rather than in a hospital. The economics are a spread rather than a margin story: the company is paid a negotiated rate by a third party — the payer, not the patient — and out of that rate it buys the drug and employs the clinical labour that administers it. An operating margin near 6.3% shows how narrow the resulting slice is. At $23.74 on 9 September 2026 the shares are trading rich to triangulated fair value, and the gap is wide (-28%), on 13x forward earnings with net debt of ~$1.1B ranking ahead of the equity. What decides the outcome is the reimbursement rate per therapy relative to drug acquisition cost and nursing wages — a three-way squeeze in which the company sets none of the three prices. The most damaging risk follows directly from the margin: because operating profit is such a thin slice of revenue, a reimbursement change that looks minor as a share of revenue is very large as a share of profit.

Narrative drafted 2026-08-16 by claude-opus-5 under supervision; reviewed by Marinus 2026-08-16.

The dashboard below is the whole argument on one page: spot ($23.74) against each valuation anchor, the scenario tree, technicals and the options-implied move.

Anti-Thesis (The Real Bear Case)

The bear mechanism is a rate cut the company cannot refuse. Payers periodically reprice therapy categories, and a provider whose operating margin is near 6.3% converts a modest rate reduction into a disproportionate earnings decline, because the drug cost sitting inside that rate is largely fixed. Clinical labour compounds it from the other side: nursing wages are set by a wider labour market and are sticky downward, so cost inflation persists straight through a revenue reset. Mix is the quieter version of the same problem — growth carried by high-cost therapies raises revenue while diluting the percentage margin, which flatters the top line and does nothing for profit. Leverage then decides who absorbs the shortfall: with net debt of ~$1.1B fixed against a cash flow that is not, the equity takes all of it. The model's structural branch targets a level below the 52-week low.

Key Debate

Gross Margin explains 64% of Monte Carlo outcome variance — the single variable that decides which side is right.

What the Market Is Pricing In

At the current price, the market pays 12.6× consensus forward EPS, vs the house DCF terminal 10.0×, and a peer median 18.7×. The house DCF sits 45% below spot, so the market is pricing in more than the house case — roughly 8.8pp of revenue CAGR.

Variant perception: the house view is below-consensus, and the thesis is primarily multiple-driven.

Scenario Analysis

The scenario tree spans a structural 'Structural — Reimbursement Cuts / Labor Inflation' downside ($9.40) to a 'Bull — Re-Rate / Deleveraging' bull case ($37.79); the probability-weighted blend (PWEV $21.36) is -10% versus spot.

Share-count charge: none applied. The probability-weighted value above is the gross per-share figure — no annual dilution is deducted — stock-based compensation runs at 0.7% of revenue; free cash flow net of SBC is $0.18B. SBC is therefore disclosed, not charged: read the per-share figures as before dilution.

Scenario rationale — the driver path behind every target:

• Structural — Reimbursement Cuts / Labor Inflation (20%, $9.40). Structural impairment — reimbursement cuts / labor inflation: earnings AND the multiple compress together. Target sits below the 52-week low by construction.
• Volume / Payer-Mix Recession (17%, $15.96). Cyclical downturn — patient volumes/acuity + reimbursement (Medicare/commercial) + labor costs + leverage weakens for 1–2 years before normalising.
• Base — Admissions + Pricing (35%, $22.17). Mid-cycle — normalised patient volumes/acuity + reimbursement (Medicare/commercial) + labor costs + leverage; disciplined capital allocation; steady returns.
• Growth — Volume Recovery / Service-Line (20%, $29.93). Upside — volume recovery + deleveraging lifts earnings above mid-cycle; the multiple expands modestly.
• Bull — Re-Rate / Deleveraging (8%, $37.79). Upside tail — sustained tight conditions or a structural re-rate on volume recovery + deleveraging.

Valuation Triangulation

Three weighted anchors — an intrinsic dcf, a scenario-weighted pwev and a monte carlo median (student-t + regime switching) — read them with their basis in mind. The Monte Carlo, the DCF terminal and any peer re-rate key off a market multiple, so they are not fully independent; only discounted cash flows themselves are genuinely multiple-free. The discipline is to read the spread and weight the cash-based view, not to treat three numbers as three independent votes.

The house blend DECLARES five anchor weights — DCF 35%, scenario PWEV 25%, Monte Carlo 15%, sum-of-parts 15%, peer re-rate 10%. For this name sum-of-parts, peer P/E re-rate are not computed, so 25% of the declared weight is redistributed across the anchors that exist — which is why the weights above differ from the declared ones. The fair value is unaffected by this disclosure; the blend has always worked this way.

Peer EV/Revenue re-rate — 0% weight: it duplicates the peer-multiple information already carried by the Peer P/E anchor while ignoring margin mix; weighting both would double-count the peer view. Shown as a cross-check.

Monte Carlo — the outcome distribution

10,000 paths, Student-t shocks (fat tails) with a regime-switching overlay. The median lands at $18.77 and 35% of paths finish above spot. The variance decomposition shows the gross margin is the dominant swing factor (64% of variance). The fundamental driver, not the multiple, sets the spread — a cleaner setup.

DCF — the cash-flow anchor

Independent of the market multiple: a 5-year path, WACC 9.0%, 10.0x terminal FCF multiple → $13.09. This anchor is deliberately the heaviest (47%): it is the valuation least hostage to the current multiple regime.

Peer benchmarking — relative value

Against the peer cohort, re-rating to the peer-median EV/Revenue multiple implies $72.87; the peer-median forward P/E is 18.7x, but the engine carries no P/E-implied price for this name (no forward-EPS basis at the peer step). A premium is only justified by superior growth/margins; otherwise it is multiple risk. Excluded from the weighted blend — shown only as a market cross-check.

Across all anchors the spread is 280% of the median — wide (genuine disagreement — the blend carries low valuation confidence).

Sensitivity

DCF/share — WACC × terminal multiple

DCF/share — revenue CAGR Δ × op-margin Δ

Tornado — DCF/share swing by driver (widest first)

Company lever — SoP/share vs Care Delivery & Health Facilities multiple (AI re-rating) (base 12.0x)

Peer Quality & Weighting

Quality-weighted forward P/E: 15.2× (simple median 18.7×). Direct peers count 100%, segment 50%, broad 25%.

Historical-range cross-check: 52-week range $18.01–$36.80, centre $25.70 (+8% vs spot); spot sits at the 30th percentile of the range. Low-weight mean-reversion cross-check, not a fundamental anchor.

Risk / Reward & Margin of Safety

That ratio compares triangulated upside against the probability-weighted bear target, not the extreme tail; with a leg missing it is withheld rather than computed from a magnitude. Bull case (Bull — Re-Rate / Deleveraging): $37.79.

Company Overview & Business Model

Option Care Health Inc — HEALTHCARE · MEDICAL CARE FACILITIES. Option Care Health, Inc. offers infusion services at home and at alternative sites in the United States. The company is headquartered in Bannockburn, Illinois.

How it makes money.

Edge. Narrow moat — inferred from a 6.3% operating margin and the hospital / dialysis operations business model. Some pricing power / share stability; terminal multiple near the market.

Revenue-Segment Breakdown

The company-specific drivers behind the valuation — each segment carries its own growth, margin, multiple and capex intensity. (Tags: FACT reported · ESTIMATE from disclosures · INFERENCE judgment.)

Named Exposures

Demand & pricing cycle (FACT/ESTIMATE)

Capital intensity & shareholder returns (ESTIMATE)

Structural risk vs optionality (INFERENCE)

Industry Context — Health Care — Payers Providers

This name sits in the Health Care — Payers Providers cluster as a care delivery & health facilities name. patient volumes/acuity + reimbursement (Medicare/commercial) + labor costs + leverage. Its scenarios are not guessed in isolation — they inherit a single, shared view of the cluster's driver cycle, so the names that depend on the same event are mutually consistent.

Value chain: THC (care delivery & health facilities) · EHC (care delivery & health facilities) · ENSG (care delivery & health facilities) · HQY (managed care / health services) · OPCH (care delivery & health facilities)

Mapping note: name-level 'Structural — Reimbursement Cuts / Labor Inflation' (20%) + 'Volume / Payer-Mix Recession' (17%) map to cluster Cost-Trend Spike / Reimbursement-Reform Squeeze (37%); name-level 'Growth — Volume Recovery / Service-Line' (20%) + 'Bull — Re-Rate / Deleveraging' (8%) map to cluster Upside — Margin Recovery / Care-Services (28%) — the cluster row is the SUM of the mapped scenario probabilities, not a different estimate.

On the cluster's key downside — Cost-Trend Spike / Reimbursement-Reform Squeeze — this name implies 37% vs the cluster house view of 37% (in line with the house). The cluster's full cross-stock reconciliation governs that the names which ride the same capex cycle assign it comparable odds.

Structure: Shared State — The Health Care — Payers Providers cycle is the shared macro driver. Driver — medical-cost trend (MLR) + utilization + reimbursement/regulation. Dispersion — Members differ by cyclicality (quality compounders vs deep cyclicals).

Balance Sheet & Liquidity

Balance-sheet data as of 2025-12-31 (Alpha Vantage).

Capital Allocation

Free-Cash-Flow Quality

Accounting quality: SBC 1% of revenue; cash conversion (OCF/NI) 124% — cash-backed.

Earnings-Call Disconfirmation & Sentiment

Derived signals from the MCH market-data store (Alpha Vantage transcripts + news). Quantitative tone only — a disconfirmation flag, not a substitute for reading the call.

Management vs analyst tone (2026Q1): management +0.18 vs analyst floor +0.00 → delta +0.18 (n=25 mgmt / 14 Q&A; 7th pctile across the S&P book, z -1.4).

Flag: CANDID — management unusually candid/cautious vs peers (relatively low spin).

News (last 365d, 334 articles): avg ticker sentiment +0.13 (bullish 26% / bearish 12%)

Consensus & Market Expectations

_Consensus figures: Alpha Vantage sell-side aggregates. Where the house view sits materially above or below the street, the divergence is itself a datum — see the thesis.

Catalyst Calendar

• 2026-10-29 (~51d) — Quarterly earnings — est. EPS $0.44 (AV EARNINGS_CALENDAR)

Forecast Track Record

• EPS surprise: beat 88% of the last 8 quarters; average surprise +6.0%.
• Prior-forecast backtest (18 snapshots, 2026-07-21→2026-09-03): directional hit-rate 28%; mean predicted -8.4% vs realised +1.8%. Disconfirming track record is reported, not suppressed.

Catalyst Timeline

5 catalysts in the next 90 days (of 13 tracked). Importance 1–3; confidence 0–1.

_Sources: extended.catalysts, data/catalysts/.json, data/catalysts/macro.json, AV DIVIDENDS, opex 3rd-Friday calc.

Scenario Macro & Key Risks

Decision Rules (Machine-Checked)

Stance: Hold — 0 bullish / 0 bearish / 0 caution rules triggered of 6 evaluable (0 lacked data).

Machine-checked rules over disclosed inputs. The authored falsification triggers elsewhere in this report are analyst judgment and are NOT evaluated here. The stance is a portfolio-management signal and does not modify the published research rating.

Reasons the Thesis Could Fail (Falsifiable)

Pre-registered signals that would break the thesis — each polices a specific scenario boundary and is checked at every earnings update:

• Organic revenue growth / order backlog < flat-to-negative for two consecutive quarters (2 consecutive prints). Sustained demand rollover breaks the base case toward the recession scenario.
• FY revenue ($B) < 5.8 (next reported fiscal year). (rationale withheld pending re-authoring — frozen figure or verdict)
• Probability-weighted fair value (PWEV) at the next re-run < 23.74 (any scheduled re-run). (rationale withheld pending re-authoring — frozen figure or verdict)

Fact / Inference / Speculation

• FACT: Spot $23.74; 52-week range $18.01–$36.80; engine rating SELL; house target $21.36 (-10%). (source: Alpha Vantage 2026-09-08, 9 September 2026)
• INFERENCE: Triangulated FV $16.98 (-28% vs spot · triangulated FV); the rating tracks the Monte-Carlo + scenario-PWEV core; the cash-flow anchor sits below the multiple-discipline core.
• SPECULATION: At current prices the embedded bet is that Gross Margin keeps surprising favourably — an operating call the next two prints will test.

Conviction Score

Research Conviction measures the strength and quality of the research setup — input coverage, financial quality, valuation support, process agreement. It is NOT the probability that the recommendation succeeds; the forecast track record section is the evidence on that.

54.3/100 (confidence band 44.0–64.5), 35th percentile of 893 covered names (as of 2026-09-08). Weighted composite under config ros-1.20.0 — every component and its inputs below.

Score history: 54.0 → 53.5 → 53.8 → 53.7 → 53.8 → 53.4 → 54.1 → 54.3.

Probability-Weighted Return Profile

Horizon: 1 year — at this horizon CAGR equals total return by definition. Expected values are the probability-weighted sums over the full scenario set below.

The gross expected return is the probability-weighted scenario return (it reconciles to the gross PWEV); the diluted figure applies the SBC share-count charge and matches the published PWEV-based target.

Expected Alpha

Expected return minus the return this name is REQUIRED to deliver for its risk (1-year horizon). Constants are pre-registered (preregistered-static (amendment #2, 2026-07-29); not fitted to MCH outcomes).

A negative expected alpha does not change the rating — it says the expected return does not clear the risk-adjusted hurdle at today's price. Rating mechanics are unchanged by this section.

Probability Cross-Checks

Not authoritative. The scenario probabilities in this report are AUTHORED — a judgement about how the world might go, not a measurement. Nothing below modifies them, the target, the rating or any position size. These checks ask only whether anything outside our own model agrees with us; where it does not, that is information for the reader, not a correction we have quietly applied.

Authored set: 5 scenarios, probabilities summing to 1.0, mean target $21.36.

Factor Exposures

Cross-sectional percentiles over 893 covered names (style scores sector-demeaned; thematic = return-beta to the theme's proxy ETF). 50 = estate median.

Market interaction: correlation vs SPY +0.17, vs QQQ +0.10 (trailing ~1y daily returns).

Options Intelligence

Preferred structure: Protective Put. The selector reads the equity view (direction) and the volatility surface — nothing here re-prices the chain.

• bearish/holder — hedge the position; a collar finances the put by capping upside
• Direction bearish from the overlay conviction/rating (read-only input).
• IV/RV at the 65th percentile of the cross-section → mid vol bucket. This is the measure that selects the structure above: it ranks how rich this name's implied vol is against its own realised vol, relative to other names.
• Reported alongside and not used to select: this name's own ATM IV sits at the 54th percentile of its own month-end history (decile 6).
• IV term structure is in contango (longer-dated richer, slope +13.6pp) — favour longer-dated ownership (LEAPS) or calendars that are long the cheaper front.
• No live-chain Protective Put was priced for this name — shown as the indicated strategy; size against a freshly pulled chain.

IV term structure (contango, slope +13.6pp): 38-DTE 35% · 129-DTE 44% · 220-DTE 48%

No live-chain Protective Put was priced for this name — shown as the indicated approach; size against a fresh chain.

Alternatives: Collar, Put Debit Spread. IV rank shown via the name's own monthly IV history (advisory); structure selected on the cross-sectional IV/RV percentile. Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Position Sizing Framework

research rating is SELL-tier — the model carries no long position.

Model output for research and education only — not individualised investment advice. Position-sizing and stance figures are mechanical outputs of the disclosed rules and inputs; they do not consider any person's objectives, financial situation, or tax status.

Options Overlay

A defined-risk way to express the SELL equity view. Chain as of 2026-09-08 — end-of-day marks — indicative, not executable quotes.

Market signals — ATM IV 34.7% (moderate regime) · expected move ±9.4% (2026-10-16) · put/call OI 0.14 · ATM Δ 0.71 / Θ -0.01 / ν 0.03 · next earnings 2026-10-29. Direction: NEUTRAL (implied return -28.5% to triangulated fair value $16.98).

Covered Call (if held) (Income / neutral) — Short 25 C · 2026-10-16 · premium $0.6 · yield 2.5% · priced from the listed chain (EOD marks)

Converts a near-fair holding into income by agreeing to sell at a higher strike — worth weighing when upside looks limited near fair value and being called away is acceptable. Illustrative — no outcome is implied or guaranteed.

Put Spread (income) (Income / would-own) — Short 22.5 P / Long 20 P · 2026-10-16 · net $0.08 · net entry $22.43 · yield 0.3% · RoR 3.0% · max loss $2.42 · priced from the listed chain (EOD marks)

Gets paid to wait for a lower entry, with the tail capped: the sold put collects premium while the cheaper long wing below it caps the maximum loss at the spread width — a defined-risk alternative to a naked cash-secured put.

Protective Collar (if held) (Hedge) — Long 22.5 P / Short 25 C · 2027-04-16 · net $0.6 · floor -5.0% · cap +5.0% · priced from the listed chain (EOD marks)

For a holder who wants to stay invested but cap risk: the sold call funds most of the protective put, fencing the position into a band — a way to ride out a de-rating without selling.

Indicative options structures — a defined-risk expression of the equity view, model-and-market illustrated from the last-close chain. NOT personalised advice or an executable quote; premiums, IV and greeks move intraday. Options carry the risk of total loss of premium. Not a registered financial adviser.

Rating Bridge

Rating = SELL because:

• Probability-weighted scenario value implies -10% vs spot
• Monte Carlo median implies -21% vs spot
• DCF fair value implies -45% vs spot — but this is terminal-value sensitive (exit-multiple $13.09 vs Gordon $20.43, 56% apart), so it carries less weight
• Bear case (Structural — Reimbursement Cuts / Labor Inflation) downside is -60% vs spot
• Net: the valuation anchor itself sits 28.5% below spot, so there is no reward leg to weigh against the bear case and the reward-to-risk ratio is withheld rather than computed off a negative upside. The rating warrants a Sell.

Model Appendix

DCF — line items

FCF is bridged: NOPAT + D&A − Capex − ΔNWC (capex intensity 7% of revenue, weighted from the segments) — not a single conversion fudge.

WACC 9.0% · Σ PV(FCF) $1B + PV(terminal) $2B = EV $3B; − net debt $1.1B → equity $2B ÷ diluted shares $0.16B = $13.09/share (exit-multiple terminal).

• Gordon terminal at 2.5% → $20.43/share — a genuinely non-multiple, cash-based cross-check; the exit-multiple and Gordon values bracket the terminal-value risk.
• Incremental ROIC on the forecast capex ≈ 3% vs WACC 9.0% → below WACC — the incremental build is value-dilutive.

Peer set

Implied prices at the peer medians: EV/Rev → $72.87 (no P/E-implied price — no forward-EPS basis at the peer step).

Weighted fair-value math

Assumption Register

Sensitivity-ranked drivers (widest fair-value swing first): Op margin ±3pp (20.0); Capex intensity ±15% (9.0); Terminal × ±15% (4.0); WACC ±1pp (2.0); Revenue CAGR ±3pp (2.0).

Inputs, Sources & Confidence

Every load-bearing input, labelled by type and confidence. (reported fact · company guidance · consensus estimate · market data · house estimate · inference.)

Research Provenance

Load-Bearing Assumptions

DCF: WACC 9.0%, terminal multiple 10×, FY+5 revenue $7B. Triangulation leans 47% on DCF, 33% on PWEV, 20% on the Monte Carlo median.